Updated on 6 September 2012
Mr Stuart A Randle, president and CEO, GI Dynamics
Type 2 diabetes, also known as non-insulin dependent diabetes mellitus, is a lifelong disease. US-based GI Dynamics is a pioneer in the development of an effective, non-surgical treatment for type 2 diabetes and obesity. Its EndoBarrier Therapy is a novel approach that doesn't rely on medication or surgery to help patients regain control of type 2 diabetes and obesity. Currently, GI Dynamics markets EndoBarrier in select regions in Europe, South America and Australia. In April 2012, the first group of patients were treated in Australia with EndoBarrier Therapy who were successfully implanted with the EndoBarrier.
Mr Stuart A Randle, president and CEO, GI Dynamics talks to BioSpectrum about this novel therapy to treat type-2 diabetes and obesity, and about the future plans of the company in taking this therapy to a broader market.
Tell us in detail about EndoBarrier Therapy.
EndoBarrier Therapy is a revolutionary approach to treating type 2 diabetes and obesity. This therapy doesn't rely on medication or involve surgery. Delivered and removed endoscopically (i.e., through the mouth), the EndoBarrier device is a flexible, tube-shaped liner that creates a barrier between ingested food and the duodenum or proximal jejunum sections of the intestine. Essentially, EndoBarrier mimics the effects of a gastric bypass, but without the risks associated with surgery. There are no incisions, scars or lasting changes to the anatomy.
The implant procedure usually takes less than 30 minutes; and most patients go home the same day. Once implanted, EndoBarrier affects certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety; and these changes allow for rapid and sustained improvement of type 2 diabetes and weight loss.